March 14, 2025

FDA Recommends Influenza Vaccine Strains for 2025 to 2026

The FDA has selected influenza vaccine strains for the 2025 to 2026 U.S. flu season, maintaining consistency with prior formulations while incorporating updated epidemiologic and antigenic data to optimize protection.

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters

March 12, 2025

Tobacco Use Higher Among Adults With Disabilities, Study Finds

Despite declines in tobacco use, adults with disabilities had higher usage rates. Differences in use across cumulative disabilities persisted or worsened, the study found.

Conexiant

March 11, 2025

FDA's New Pulse Oximeter Guidance: Stricter Standards, Ongoing Challenges

The FDA's 2025 pulse oximetry guidance introduces stricter accuracy standards, larger study cohorts, and objective skin pigmentation assessment to address measurement bias in darker-skinned patients.

Conexiant

March 11, 2025

Doctors Never Truly Vacation, Study Reveals

"Organizations should implement strategies to minimize clinical tasks during PTO."

Conexiant

March 07, 2025

FDA Approves First Xolair Biosimilar

New interchangeable treatment option Omlyclo now available for patients with allergic asthma, chronic hives, nasal polyps, and food allergies; carries same boxed warning for anaphylaxis as original medication.

Conexiant

March 06, 2025

Tezepelumab Shows Promise for Severe CRSwNP in Phase 3 Trial

The WAYPOINT trial provides strong evidence that tezepelumab effectively reduces nasal polyp size, congestion, and overall symptom burden in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps

Conexiant

March 06, 2025

An Estimated 31 Million Americans Borrowed for Medical Bills in 2024

A new West Health-Gallup Survey survey reveals insights into medical debt across all income levels and demographics in the United States.

Conexiant

March 06, 2025

FDA Approves First Needle-Free Epinephrine for Kids

FDA approves neffy 1 mg, the first needle-free intranasal epinephrine spray for pediatric anaphylaxis.

Conexiant